Attached files

file filename
EX-31.2 - EX-31.2 - BELLICUM PHARMACEUTICALS, INCa2020q2exh312.htm
EX-31.1 - EX-31.1 - BELLICUM PHARMACEUTICALS, INCa2020q2exh311.htm
EX-10.2 - EX-10.2 - BELLICUM PHARMACEUTICALS, INCexh102-2019equityincen.htm
EX-10.1 - EX-10.1 - BELLICUM PHARMACEUTICALS, INCexh101-directorcompens.htm
EX-3.1 - EX-3.1 - BELLICUM PHARMACEUTICALS, INCexh31-amendedandrestat.htm
10-Q - 10-Q - BELLICUM PHARMACEUTICALS, INCblcm-20200630.htm

Exhibit 32.1
 
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (the “Report”) of Bellicum Pharmaceuticals, Inc. (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, the undersigned, in their capacities as officers of the Registrant, do each hereby certify, that, to the best of such officer’s knowledge:
(1)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
 
/s/ Richard A. Fair
Richard A. Fair
President and Chief Executive Officer
(Principal Executive Officer)
August 6, 2020
/s/ Atabak Mokari
Atabak Mokari
Chief Financial Officer
(Principal Financial Officer)
August 6, 2020
 
 
This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.